| answer text |
<p>As part of the consultation process undertaken in 2020 and 2022, we updated the
Branded medicines: statutory scheme. Impact assessments were conducted to understand
the drivers of changes to measured sales in the voluntary scheme for branded medicines
pricing and access (VPAS).</p><p> </p><p>The 2020 and 2022 assessments are available
at the following links:</p><p> </p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/871361/final-impact-assessment-statutory-scheme-2020.pdf"
target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/871361/final-impact-assessment-statutory-scheme-2020.pdf</a></p><p>
</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1079733/Statutory_Scheme_impact_assessment_medicine_pricing_v3.0_FINALdated_May_2022.pdf"
target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1079733/Statutory_Scheme_impact_assessment_medicine_pricing_v3.0_FINALdated_May_2022.pdf</a></p><p>
</p><p>Under the rules of VPAS, there is no requirement for regular assessment of
whether scheme members’ profits exceed the margin of tolerance. Under the 2014 Pharmaceutical
Price Regulation Scheme where such a requirement was in place, no companies were found
to have exceeded the margin of tolerance in 2017 or 2018.</p>
|
|
